Propylone

Propylone
Clinical data
Other names	3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA
Drug class	Monoamine releasing agent; Monoamine reuptake inhibitor
Identifiers
	IUPAC name 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one;
CAS Number	201474-93-3;
PubChem CID	85764579;
ChemSpider	129433781;
UNII	TBJ4S8YF37;
Chemical and physical data
Formula	C13H17NO3
Molar mass	235.283 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCNC(C)C(=O)C1=CC2=C(C=C1)OCO2;
	InChI InChI=1S/C13H17NO3/c1-3-6-14-9(2)13(15)10-4-5-11-12(7-10)17-8-16-11/h4-5,7,9,14H,3,6,8H2,1-2H3; Key:YFVKHKCZBSGZPE-UHFFFAOYSA-N;

Propylone, also known as 3,4-methylenedioxy-N-propylcathinone is a mixed monoamine releasing agent and reupake inhibitor of the cathinone family related to methylone and ethylone.^[1]

It acts specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) values for induction of monoamine release of 3,128 nM (30%) for serotonin and 976 nM (20%) for dopamine, and IC₅₀Tooltip half-maximal inhibitory concentration value for monoamine reuptake inhibition of 2,462 nM for serotonin, 28,540 nM for norepinephrine, and 1,863 nM for dopamine.^[1]

The drug was first described in the literature in a 1996 patent by Alexander Shulgin and Peyton Jacob III.^[2] It was subsequently characterized more thoroughly by 2015^[1] and was encountered as a novel designer drug in Europe by 2016.^[3]^[4]^[5]

References

^ ^a ^b ^c Sakloth F (11 December 2015). Psychoactive synthetic cathinones (or 'bath salts'): Investigation of mechanisms of action. Theses and Dissertations (Ph.D. thesis). Virginia Commonwealth University. doi:10.25772/AY8R-PW77. Retrieved 24 November 2024 – via VCU Scholars Compass.
^ WO 1996039133, Jacob III P, Shulgin AT, "Preparation of novel N-substituted-2-amino-3′,4′-methylenedioxypropiophenones as anti-depressant and anti-parkinsonism agents.", published 12 December 1996, assigned to Neurobiological Technologies, Inc.
^ "EMCDDA–Europol 2016 Annual Report on the implementation of Council Decision 2005/387/JHA". Europol. 23 October 2018. Retrieved 11 March 2025.
^ Liu C, Jia W, Li T, Hua Z, Qian Z (August 2017). "Identification and analytical characterization of nine synthetic cathinone derivatives N-ethylhexedrone, 4-Cl-pentedrone, 4-Cl-α-EAPP, propylone, N-ethylnorpentylone, 6-MeO-bk-MDMA, α-PiHP, 4-Cl-α-PHP, and 4-F-α-PHP". Drug Test Anal. 9 (8): 1162–1171. doi:10.1002/dta.2136. PMID 27863142.
^ Pulver B, Fischmann S, Gallegos A, Christie R (December 2024). "EMCDDA framework and practical guidance for naming cathinones". Drug Test Anal. 16 (12): 1409–1435. doi:10.1002/dta.3662. PMC 11635063. PMID 38389255.

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.